January 17, 2020

Probiotec Limited (ASX:PBP) is a leading manufacturer, packer and distributor of a range of prescription and over-the-counter pharmaceuticals, medicines and consumer health products.

PBP (the “Group”) is comprised of three businesses, the parent entity Probiotec, and the subsidiaries being South Pack Laboratories (SPL) and Australian Blister Sealing (ABS).

For the past 4 years, the Group has established a new senior management team who have adopted a new strategy to divest and exit non-core operations. Furthermore, capital has been allocated to growing both organically and through acquisitions within the contract manufacturing areas. Since then, the Group has made a turnaround and is growing rapidly. The rise in return on equity from 5.36% to 8.16% in the past four years proves the quality of new senior management.

Business Segment

Probiotec (the parent entity) services a wide range of large multinational companies, including Pfizer, Proctor & Gamble, Johnson & Johnson and Blackmores. Key...

Please reload


Please reload


Any information has been prepared for the purpose of providing general information only, without taking account of any particular investor's objectives., financial situation or needs, It is not an offer or invitation for subscription or purchase, or a recommendation of any financial product and it is not to be relied on by investors in making an investment decision. Past performance is not a reliable indicator of future performance. To the extent any general financial product advice is provided in this document, it is provided by Glennon Capital Pty Ltd ACN 137 219 866, AFSL No. 338 567. An investor, before acting on anything construed as advice, should consider the appropriateness of such construction and advice having regard to their objectives, financial situation or needs..


Phone: (02) 8027 1000


PO Box R281,

Royal Exchange

NSW, 1225


Level 17

25 Bligh Street

Sydney NSW 2000

(c) 2018 Glennon Capital. All rights reserved.